Pharmacokinetics and pharmacodynamics of NTBC (2-(2-nitro-4-fluoromethylbenzoyl)-1,3-cyclohexanedione) and mesotrione, inhibitors of 4-hydroxyphenyl pyruvate dioxygenase (HPPD) following a single dose to healthy male volunteers

British Journal of Clinical Pharmacology

Volumn 52, Issue 2, 2001, Pages 169-177

  Hall, Michael G ^a   Wilks, Martin F ^b   McLean Provan, W ^a   Eksborg, Staffan ^c   Lumholt, Bo ^d  

^a ASTRAZENECA   (United Kingdom)

^b JEALOTT S HILL RESEARCH STATION   (United Kingdom)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d Swedish Orphan AB   (Sweden)

Author keywords

HPPD inhibitors; HT 1; Mesotrione; NTBC; Pharmacodynamics; Pharmacokinetics; Triketones; Tyrosine

Indexed keywords

2 (2 NITRO 4 FLUOROMETHYLBENZOYL) 1,3 CYCLOHEXANEDIONE; 2 (4 METHYLSULFONYL 2 NITROBENZOYL) 1,3 CYCLOHEXANEDIONE; 4 HYDROXYPHENYLPYRUVATE DIOXYGENASE; ENZYME INHIBITOR; HERBICIDE; MESOTRIONE; TYROSINE; UNCLASSIFIED DRUG;

ADULT; AMINO ACID BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG FORMULATION; DRUG HALF LIFE; DRUG TOLERABILITY; HUMAN; HUMAN EXPERIMENT; MALE; METABOLITE; MULTICENTER STUDY; NORMAL HUMAN; PARAMETER; PRIORITY JOURNAL; TYROSINEMIA; URINARY EXCRETION;

4-HYDROXYPHENYLPYRUVATE DIOXYGENASE; ADMINISTRATION, ORAL; AREA UNDER CURVE; CHEMISTRY, PHARMACEUTICAL; CYCLOHEXANONES; ENZYME INHIBITORS; HALF-LIFE; HUMANS; MALE; NITROBENZOATES; THERAPEUTIC EQUIVALENCY; TYROSINE; TYROSINEMIAS;

EID: 0034836917     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0306-5251.2001.01421.x     Document Type: Article

References (14)

1. The discovery and structural requirements of inhibitors of p-hydroxyphenylpyruvate dioxygenase
2. Evaluation of the mechanism of action of the bleaching herbicide SC-0051 by HPLC analysis
3. The effect of NTBC on enzymes involved in tyrosine catabolism in the rat
4. Urinary excretion of deuterated metabolites in patients with tyrosinaemia type 1 after oral loading with deuterated L-tyrosine
5. Inhibition of 4-hydroxyphenylpyruvate dioxygenase by 2-(2-nitro-4-trifluoromethylbenzoyl) -cyclohexane-1, 3-dione and 2-(2-chloro-4-methanesulphonylbenzoyl)-cyclohexane-1,3-dione)
6. On the enzymic defects in hereditary tyrosinemia
7. Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase
8. Metabolism of 2-(4-methylsulphonyl-2-nitrobenzoyl) -1,3-cyclohexanedione (mesotrione) in the rat and mouse
9. PITMAN: A FORTRAN program for exact randomization tests
10. Use of confidence intervals in analysis of comparative bioavailability
11. Symmetrical confidence intervals for bioequivalence trials
12. A distribution-free procedure for the statistical analysis of bioequivalence studies
13. Diagnosis and management of tyrosinaemia type I